Statement: All of the adverse events recorded in the primary trial were cardiac related.
Primary_evidence: Adverse Events 1:   Total: 5/45 (11.11%)   Neutrophils/granulocytes (ANC/AGC) *  [1]0/45 (0.00%)   Neutrophils/granulocytes (ANC/AGC) *  [2]0/45 (0.00%)   Diabetes decompensation * 0/45 (0.00%)   Diarrhea *  [2]0/45 (0.00%)   Mucositis/stomatitis and Vomiting *  [3]0/45 (0.00%)   Pancreatitis *  [4]1/45 (2.22%)   Febrile neutropenia *  [2]3/45 (6.67%) Adverse Events 2:   Total: 0/46 (0.00%)   Neutrophils/granulocytes (ANC/AGC) *  [1]0/46 (0.00%)   Neutrophils/granulocytes (ANC/AGC) *  [2]0/46 (0.00%)   Diabetes decompensation * 0/46 (0.00%)   Diarrhea *  [2]0/46 (0.00%)   Mucositis/stomatitis and Vomiting *  [3]0/46 (0.00%)   Pancreatitis *  [4]0/46 (0.00%)   Febrile neutropenia *  [2]0/46 (0.00%)   Infection pulmonary/ Upper airway NOS *  [5]0/46 (0.00%)